Doceptor 80 mg (Docetaxel) Injection

Introduction to Doceptor 80 mg (Docetaxel) Injection

Doceptor 80 mg, manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Saif Pharma, is a high-dose microtubule inhibitor chemotherapy injection designed for advanced cancer treatment. Containing the active ingredient Docetaxel, this cytotoxic agent is clinically proven for breast cancer (BC), non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC), gastric adenocarcinoma (GC), and squamous cell carcinoma of the head and neck (SCCHN). By stabilizing microtubules and disrupting mitosis, Doceptor 80 mg offers targeted efficacy in monotherapy and combination regimens.

Key Indications & Therapeutic Benefits

Doceptor 80 mg is indicated for:

• Breast Cancer (BC):
  • Metastatic BC: Single agent (60–100 mg/m²) after prior chemotherapy failure.
  • Adjuvant Therapy: Combined with doxorubicin/cyclophosphamide (75 mg/m²) for operable node-positive BC.
• Non-Small Cell Lung Cancer (NSCLC):
  • Post-Platinum Failure: Single agent (75 mg/m²).
  • First-Line Therapy: Combined with cisplatin (75 mg/m²) for untreated, unresectable NSCLC.
• Prostate Cancer: Combined with prednisone (75 mg/m²) for metastatic castration-resistant prostate cancer.
• Gastric Adenocarcinoma (GC): Combined with cisplatin/fluorouracil (75 mg/m²) for untreated advanced GC.
• Head/Neck Cancer (SCCHN): Induction therapy with cisplatin/fluorouracil (75 mg/m²) for locally advanced SCCHN.

Mechanism of Action: Docetaxel binds to tubulin, stabilizing microtubules and blocking cell division, leading to apoptosis in rapidly proliferating cancer cells.

Pharmacology & Pharmacokinetics

• Chemical Class: Taxane derivative (microtubule inhibitor).
• Metabolism: Hepatic via CYP3A4 enzymes; dose adjustments required with CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin).
• Excretion: Primarily fecal (75%) with a half-life of 11–18 hours.
• Protein Binding: >98%, ensuring prolonged tissue distribution and sustained antitumor activity.

Recommended Dosage & Administration

Standard Regimens (IV infusion over 1 hour every 3 weeks):

• Breast Cancer:
  • Metastatic: 60–100 mg/m².
  • Adjuvant: 75 mg/m² post-doxorubicin/cyclophosphamide.
• NSCLC:
  • Post-Platinum: 75 mg/m².
  • First-Line: 75 mg/m² + cisplatin 75 mg/m².
• Prostate Cancer: 75 mg/m² + prednisone 5 mg twice daily.
• Gastric Cancer: 75 mg/m² + cisplatin/fluorouracil.
• SCCHN: 75 mg/m² + cisplatin/fluorouracil (3–4 cycles).

Critical Guidelines:

1. Premedication: Administer oral corticosteroids (e.g., dexamethasone 8 mg twice daily for 3 days) to reduce hypersensitivity and fluid retention.
2. Contraindications: Avoid in patients with neutrophil counts <1500/mm³ or hypersensitivity to polysorbate 80.
3. Infusion: Use non-PVC equipment and a 21-gauge needle for preparation.

Drug Interactions & Precautions

• CYP3A4 Modulators: Adjust dose with strong inhibitors (e.g., clarithromycin) or inducers (e.g., phenytoin).
• Hepatic Impairment: Avoid in severe cases (bilirubin >1.5x ULN or ALT/AST >3.5x ULN).
• Hypersensitivity: Monitor for anaphylaxis; discontinue infusion if severe reactions occur.

Contraindications & Safety Warnings

• Neutropenia: Baseline neutrophil count must be ≥1500/mm³.
• Hypersensitivity: Contraindicated in patients with prior severe reactions to taxanes or polysorbate 80.
• Pregnancy/Lactation: Category D – teratogenic; avoid in pregnancy and breastfeeding.

Critical Warnings:

1. Myelosuppression: Severe neutropenia (90% incidence) and febrile neutropenia (10–15%).
2. Fluid Retention: Managed with premedication (e.g., dexamethasone).
3. Neurotoxicity: Peripheral neuropathy (40%) and sensory deficits.
4. GI Toxicity: Severe diarrhea (40%), mucositis (35%), and rare ischemic colitis.

Common Side Effects

• Hematologic: Neutropenia (90%), anemia (70%), thrombocytopenia (10%).
• Gastrointestinal: Nausea (50%), diarrhea (40%), mucositis (35%).
• Dermatologic: Alopecia (60%), nail changes (30%).
• Neurologic: Peripheral neuropathy (40%), dysgeusia (25%).
• Other: Fluid retention (50%), fatigue (60%), myalgia (25%).

Storage & Handling

• Storage: Store at 2–25°C; protect from light. Freezing does not affect stability.
• Stability: Stable for 28 days post-dilution at 2–8°C.

Why Choose Doceptor 80 mg from Saif Pharma?

Saif Pharma, a leading global distributor of oncology medications, partners with Eskayef Pharmaceuticals Ltd.—a WHO-GMP-certified manufacturer under Bangladesh’s Transcom Group—to deliver high-quality, affordable chemotherapy drugs to 60+ countries, including the USA, Canada, UAE, and India. Eskayef’s 31-year legacy of producing world-class medicines ensures Doceptor 80 mg meets international safety and efficacy standards.

Clinical Advantages of Docetaxel

• Broad Spectrum: Effective against hormone-resistant and metastatic cancers.
• Synergy in Regimens: Enhances outcomes with cisplatin, fluorouracil, and anthracyclines.
• Survival Benefit: Proven to improve progression-free survival in breast, lung, and prostate cancers.

Patient Management Tips

• Premedication: Dexamethasone 8 mg twice daily for 3 days starting 1 day before infusion.
• Monitoring:
  • Blood Counts: Weekly CBC to detect neutropenia.
  • Liver Function: Regular LFTs for patients with hepatic impairment.
  • Neuropathy Assessments: Baseline and periodic neurologic exams.

Overdose Management

Overdose may exacerbate neutropenia, neuropathy, or mucositis. Manage with therapeutic G-CSF and symptomatic care; no specific antidote exists.

Conclusion

Doceptor 80 mg (Docetaxel) Injection by Eskayef Pharmaceuticals is a cornerstone of modern oncology, offering precision and potency against advanced malignancies. For authentic, cost-effective access, trust Saif Pharma—your global partner in cancer care.